Skip to main content
Equibles
EIKN logo

EIKN · Eikon Therapeutics, Inc.

Track EIKN — free

Use EIKN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EIKN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.54 +0.21 (+2.86%)
Russell 2000 member Rebalance outlook locked
Market Cap
$408.40M
Shares
54.17M
Volume · Oct 5 485.32K Avg daily vol (3M) 484.71K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.33 Open$7.55 Day$7.07–7.55 Available close range$7.33–16.26 Avg vol 30d585K Short int5.5M · 10.1% float · 9.3d Short vol74% DataFeb 2026–Oct 2026 Filing10-Q · Aug 13

The closing range uses available history since Feb 5, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
10.1%
Latest settlement · 9.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 50-day avg −25%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −33%
trailing
6-month return −26%
trailing
Relative strength −38%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+48% holders QoQ · +37 funds added
Insider flow Accumulating
Net +$1.0M over 90 days · 0% sells
Short interest Rising
10.07% of float · ▲ +3.3% MoM · 9.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
77 holders — 13F breadth
Squeeze score 59
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 90%
annualized · 1-yr
Max drawdown −55%
past year
ATR 9.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
3 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−25% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+48% holders QoQ · +37 funds added
Insider flow Accumulating
Net +$1.0M over 90 days · 0% sells
Short interest Rising
10.07% of float · ▲ +3.3% MoM · 9.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
77 holders — 13F breadth
Price context
position in its available closing range
Range low $7 Now $7 · 0% Range high $16
vs 50-day avg -25%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EIKN
Eikon Therapeutics, Inc.
this stock
$408.40M — — — 10.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
77
% held
48.9%
Net QoQ
+2.7M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
100
View
Short & Settlement
Short Interest Rising
Shares short
5.5M
Days to cover
9.3d
Change
+171.7K sh
View
Short Volume
Short vol %
74%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
3.6K
Value
$32.1K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
46.0%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$1.0M
Buyers / Sellers
1 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 15, 2026
This year
12
View
Exempt Offerings
Offering
$400.0M
Filed
Feb 28, 2025
View
Earnings & Events
Webcasts
Last webcast
Sep 15, 2026
View

Performance

5D 20D 120D MTD YTD
EIKN -7.5% -33.1% -25.7% -8.8% —
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -7.2% -32.7% -37.9% -9.8% —
Key facts CIK 1861123 CUSIP 282564103 13F (30d) 3 filings 3 filers Visit website Investor relations